Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Jul;33(7):1190-1191.
doi: 10.1038/s41433-019-0387-1. Epub 2019 Mar 4.

Comment on: Clinical outcomes in Caucasian patients with polypoidal choroidal vasculopathy

Affiliations
Comment

Comment on: Clinical outcomes in Caucasian patients with polypoidal choroidal vasculopathy

H D Jeffry Hogg et al. Eye (Lond). 2019 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

JH: Unrelated travel grant from Bayer. SJT: Bayer—advisory board, travel support, research support; Novartis—advisory board research support; Roche—Research support. None of these relates to this work directly.

Figures

Fig. 1
Fig. 1
Porcupine plot showing 48-month visual outcomes in 29 eyes with polypoidal choroidal vasculopathy receiving Anti-VEGF intravitreal injections, PDT or both. VEGF vascular endothelial growth factor, PDT photodynamic therapy, ETDRS early treatment of diabetic retinopathy study

Comment on

References

    1. Agorogiannis Eleftherios I., Pearce Ian A., Yadav Sohraab, Parry David G., Beare Nicholas A. V. Clinical outcomes in Caucasian patients with polypoidal choroidal vasculopathy. Eye. 2018;32(11):1731–1739. doi: 10.1038/s41433-018-0168-2. - DOI - PMC - PubMed
    1. Cheung CMG, Lai TYY, Ruamviboonsuk P, Chen SJ, Chen Y, Freund KB, et al. Polypoidal choroidal vasculopathy: definition, pathogenesis, diagnosis, and management. Ophthalmology. 2018;125:708–24. doi: 10.1016/j.ophtha.2017.11.019. - DOI - PubMed